InvestSMART

SomnoMed Limited (ASX:SOM)

ALERT: Price-sensitive ASX Announcement for SOM
Current share price for SOM : $0.505 -0.155 (-23.48%)+
Announcement
Release
27 Feb 2026 8:12AM
Price at Release
$0.660
Full Release
download
Summary
SomnoMed Limited announced its half-year results for 1H FY26, reporting a record revenue of $60.7 million, a 13% increase from the previous year. The company experienced significant growth in Europe and North America, accounting for 54% and 40% of revenue respectively, despite a decline in APAC. EBITDA rose to $7.8 million, supported by operational efficiency and strategic investments in manufacturing. The company expanded its manufacturing capacity by over 20% and improved production turnaround times. It reaffirmed its FY26 guidance with expectations of revenue between $119 million and $126 million and EBITDA between $10 million and $12 million. Key leadership appointments were made to support future growth, with new roles of Chief Marketing Officer and Chief Transformation Officer established to drive strategic initiatives. The company remains focused on sustainable growth and maintaining its leadership in oral appliance therapy for sleep-related disorders.
Key Points
  • Record 1H FY26 revenue of $60.7 million, up 13% from 1H FY25.
  • Europe and North America are major revenue contributors, with 54% and 40% respectively.
  • EBITDA increased to $7.8 million, up 35% from the prior year.
  • Significant manufacturing investments resulted in a 20% capacity increase.
  • Reaffirmed FY26 guidance: revenue of $119m-$126m and EBITDA of $10m-$12m.
  • Key senior leadership appointments included a new Chief Marketing Officer and Chief Transformation Officer.
  • Focused on sustainable growth and leadership in oral appliance therapy for sleep disorders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.